Graphite Bio debuts corporate brand campaign with ‘Cure’ aspirations, even years ahead of drug approval
It’s tough to stand out in the gene editing field, so Graphite Bio adopted an uncommon biotech tactic — marketing.
The clinical-stage biotech — founded during the early days of the pandemic and going public just over a year ago — is still likely many years away from an approved drug. Its first, a sickle cell disease “gene correction” candidate, is currently in a Phase I/II study. Yet the biotech’s first corporate campaign rolled out this month confidently promotes its ambitions for a cure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.